Screener
Vera Therapeutics VERA EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other (expense) income, net | (432) | 386 |
| Total other income, net | 4,100 | 5,500 |
| Net loss | $(121,032) | $(51,694) |
| Other comprehensive income: | ||
| Change in unrealized gains and losses on marketable securities | (942) | 261 |
| Comprehensive loss | $(121,974) | $(51,433) |
| Net loss per share attributable to common stockholders, basic and diluted | $(1.69) | $(0.81) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 71,476,595 | 63,671,558 |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's EPS (basic)?
- Vera Therapeutics (VERA) reported EPS (basic) of -$1.69 in Q1 2026.
- How has Vera Therapeutics's EPS (basic) changed year-over-year?
- Vera Therapeutics's EPS (basic) decreased by 108.6% year-over-year, from -$0.81 to -$1.69.
- What is the long-term trend for Vera Therapeutics's EPS (basic)?
- Over 4 years (2021 to 2025), Vera Therapeutics's EPS (basic) has grown at a 17.7% compound annual growth rate (CAGR), from -$2.43 to -$4.66.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Vera Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude